Vanda Pharmaceuticals announces positive Phase III results for Hetlioz in delayed sleep-wake phase disorder
Vanda said its Phase III study met the primary endpoint with a 37.1-minute sleep onset shift versus placebo, with no new safety signals identified.
Sept 29 — Vanda Pharmaceuticals Inc said its Phase III study of Hetlioz (tasimelteon) in delayed sleep-wake phase disorder met the primary endpoint. 1 minute sleep onset shift versus placebo, and that no new safety signals were identified in the Phase III study for Hetlioz.